Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Xencor, Inc.
Xencor, Inc.
Hoffmann-La Roche
University of Michigan Rogel Cancer Center
Royal Marsden NHS Foundation Trust
Takeda
Seagen Inc.
HUYABIO International, LLC.
Merck Sharp & Dohme LLC
Bio-Thera Solutions
Transgene
Sotio Biotech Inc.
BerGenBio ASA
ImmuneSensor Therapeutics Inc.
Sanofi
Peter MacCallum Cancer Centre, Australia
GlaxoSmithKline
Grid Therapeutics
NYU Langone Health
NuCana plc
Formycon AG
NovoCure Ltd.
Seagen Inc.
Turnstone Biologics, Corp.
Genprex, Inc.
Merck Sharp & Dohme LLC
Sotio Biotech Inc.
Tufts Medical Center
MedPacto, Inc.
Inhibrx Biosciences, Inc
Bayer
Novartis
Wake Forest University Health Sciences
Novartis
ADC Therapeutics S.A.
Portage Biotech
National Institutes of Health Clinical Center (CC)
Augusta University
GlaxoSmithKline
University of Florida
Fate Therapeutics
University of Pennsylvania
BrightPath Biotherapeutics
Columbia University
4D pharma plc
National Institutes of Health Clinical Center (CC)
Hoosier Cancer Research Network
Seagen Inc.
Nektar Therapeutics
Advaxis, Inc.
Case Comprehensive Cancer Center